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Background and objectives: Nausea and vomiting during pregnancy (NVP) occur commonly. Possible harmful
side-effects of conventional medicine to the fetus create the need for alternative options to relieve NVP. This systematic
review (SR) investigated current evidence regarding orally administered ginger for the treatment of NVP. The primary
objective was to assess the effectiveness of ginger in treating NVP. The secondary objective was to assess the safety of
ginger during pregnancy.
Methods: A comprehensive electronic bibliographic database search was carried out. Randomized controlled trials
(RCTs) of the efficacy of orally administered ginger, as treatment for NVP in pregnant women at any stage of pregnancy,
published in English, were included. Two researchers independently extracted data and assessed trial quality. RevMan5
software (Cochrane Collaboration) was used for data analysis. p < 0.05 was considered statistically significant.
Results: Twelve RCTs involving 1278 pregnant women were included. Ginger significantly improved the symptoms of
nausea when compared to placebo (MD 1.20, 95% CI 0.56-1.84, p = 0.0002, I2 = 0%). Ginger did not significantly reduce
the number of vomiting episodes during NVP, when compared to placebo, although there was a trend towards
improvement (MD 0.72, 95% CI −0.03-1.46, p = 0.06, I2 = 71%). Subgroup analyses seemed to favor the lower daily
dosage of <1500 mg ginger for nausea relief. Ginger did not pose a significant risk for spontaneous abortion compared
to placebo (RR 3.14, 95% CI 0.65-15.11, p = 0.15; I2 = 0%), or to vitamin B6 (RR 0.49, 95% CI 0.17-1.42, p = 0.19, I
2 = 40%).
Similarly, ginger did not pose a significant risk for the side-effects of heartburn or drowsiness.
Conclusions: This review suggests potential benefits of ginger in reducing nausea symptoms in pregnancy (bearing in
mind the limited number of studies, variable outcome reporting and low quality of evidence). Ginger did not significantly
affect vomiting episodes, nor pose a risk for side-effects or adverse events during pregnancy. Based on evidence from
this SR, ginger could be considered a harmless and possibly effective alternative option for women suffering from NVP.
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Nausea and vomiting are very common complaints dur-
ing the early weeks of pregnancy. Due to the possible
harmful side-effects that conventional medicine may
pose to the unborn fetus, many mothers choose not to
use it, and are left helpless against this burden. Nausea
and vomiting of pregnancy (NVP) is commonly referred
to as morning sickness (although it can occur at any
time of the day or night), and affects about 80-90% of
pregnant women in varying degrees [1,2]. Most of these
women will experience both nausea and vomiting, and
some only nausea without vomiting or retching, but
vomiting alone is rare [2]. Symptoms usually appear at
4–9 weeks of gestation, reaching a peak at 7–12 weeks,
and subsiding by week 16. About 15-30% of pregnant
women’s symptoms will persist beyond 20 weeks, or
even up to the time of delivery [1,2]. Hyperemesis gravi-
darum (HG) is severe and persistent vomiting during
pregnancy, which can lead to dehydration, electrolyte
disturbances and liver damage, possible fetal damage and
in extreme cases, the death of the mother [1,3-5]. Women
with HG usually need to be hospitalized [1] and it occurs
in approximately 2% of pregnancies [1,2].
The exact cause of NVP remains unclear, and is prob-
ably multifactorial. Theories include the rapid increase
in hormones such as estrogen and human chorionic go-
nadotropin (hCG), [6] or Helicobacter pylori (H.pylori)
infection, as well as psychological and genetic predispos-
ition [2,6]. Severe NVP and HG can lead to maternal
malnourishment and weight loss, leading to negative
fetal outcomes including low birth weight and preterm
birth [1]. Maternal complications include acute renal
failure, esophageal rupture, coagulopathy and on rare
occasions, Wernicke’s encephalopathy [2]. The negative
effects of NVP described clearly show the importance of
managing and treating NVP and HG as early as possible,
and not considering NVP as merely an unpleasant part of
pregnancy that has to be endured and suffered through.
Pharmacological treatment of NVP is complicated due
to the fact that during pregnancy, many physiological
changes occur, including gastro-intestinal motility, plasma
volume and glomerular filtration [7]. These factors all in-
fluence the distribution, absorption and excretion of drugs
and due to this reason, not all drugs are safe during preg-
nancy. Many drugs cross the placenta by simple diffusion
and can affect the fetus directly [7]. Non-pharmacological
treatment of NVP includes ginger and simple lifestyle
changes that have been described in the literature [1].
Acupressure is also a safe and non-invasive treatment for
NVP, although there is a lack of evidence of efficacy [1,6].
Ginger (Zingiber officinale Roscoe) is widely used, with
the most common ailments currently being treated with
ginger including nausea, vomiting, pregnancy-associated
morning sickness, motion sickness and indigestion [8-12].There is mixed scientific evidence for the use of ginger
in NVP [8,10]. It should be noted that high doses of
concentrated ginger in the form of powder or herbal
tinctures can increase bleeding risk by decreasing platelet-
aggregation, and also increase stomach acid production,
especially if taken with other herbs or medicines with
the same effect [8,9,13]. Thus, ginger supplementation
can have additive or competitive interactions with some
medicines.
Several studies have been performed on the use of
ginger as an anti-emetic for use with post-operative
nausea and vomiting, motion sickness and vertigo and
chemotherapy-induced nausea and vomiting [8,9,11,14].
The ingestion of oral ginger in a fasting state or after
food intake results in an increase in gastro-duodenal
motility [15], which could be a possible mechanism of
action for the reduction in nausea and vomiting.
Currently no clear guidelines are available for ginger’s
use in the treatment of NVP, despite some literature
available on the subject [10,16,17]. A systematic review of
the available literature (also focusing on safety aspects)
can provide the best current evidence regarding possible
benefits or risks for the clinical use of ginger to treat NVP.
Objectives
The primary objective of this systematic review (SR) was
to assess the effectiveness of ginger in the treatment of
NVP. The secondary objective was to assess the safety of
orally administered ginger in the treatment of NVP, by
identifying adverse events or side-effects (if any), and
to classify them as major (serious complications detri-
mental to the mother or fetus), or minor (discomfort,
but manageable side-effects).
Methods
Ethics and protocol registration
As this SR utilizes data available in the public domain, it
was exempt from ethical review by the Health Research
Ethics Committee at Stellenbosch University (N11/04/127).
The protocol was registered on the PROSPERO Register
and can be viewed at http://www.crd.york.ac.uk/prospero/.
Registration number CRD42011001237.
Criteria for considering studies for this review
Types of studies and participants
Randomized controlled trials (RCTs) involving human
participants, and investigating ginger for the treatment
of NVP were included in this SR. Only studies that were
published in English were included. Trials were included
despite lack of blinding or placebo treatment. Women
suffering from NVP were included, with no restriction
on their age or stage of pregnancy (as included in the
various trials).
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Any form of orally administered ginger intervention
(fresh root, dried root, powder, tablets, capsules, liquid
extract, and tea) compared with an inert (placebo) or
active ingredient, was included.
Types of outcome measures
 Symptom scores on the subjective feeling of nausea,
measured by standardized scales or methods
[e.g. Visual Analogue Scale (VAS)].
 The incidence of vomiting episodes, measured by
daily recording.
 The general response to the treatment, measured by
standardized scales or methods (e.g. the 5-point
Likert-type scale).
 The occurrence of adverse events and side-effects.
Search methods for identification of studies
Literature searches were conducted in computerized da-
tabases from 1966 until 12 July 2013, with the help of a
qualified medical librarian. Databases searched included
Medline (accessed via Pubmed); EBSCO host, including
Academic Search Premier, CINAHL (nursing & allied
health research database), and CAB abstracts; CENTRAL
(Cochrane Central Register of Controlled Trials); Science
Direct; ISI Web of Science, ISAP (Index to South African
Periodicals – National Library of South Africa); Proquest;
Scopus Abstracts; Africa Wide; SABINET (South African
Bibliographic Information Network); Current Controlled
Trials (www.controlled-trials.com) and Clinical trials.gov
(www.clinicaltrials.gov). The author team also searched
for additional studies by searching the reference lists of
the included trials and other articles identified by the
electronic search. The final complete search word
string was: Pregnan* AND (nausea OR vomit* OR
morning sickness OR hyperemesis gravidarum) AND
(ginger OR zingiber officinale roscoe) AND (clinical trial*
OR randomized control trial* OR random allocation
OR placebo* OR random research OR comparative OR
“evaluation stud*” OR follow up OR prospective* OR control*
OR volunteer* OR single mask* OR double mask* OR treble
mask* OR tripl* mask* OR single-blind OR double-blind
OR treble blind OR tripl* blind*).
Selection of studies
Two reviewers independently assessed titles and ab-
stracts of references retrieved from the searches and se-
lected all potentially relevant studies. These potentially
relevant articles were retrieved as full text in hard copy
and assessed independently by the reviewers against the
eligibility criteria, as described earlier. Disagreements
were resolved with discussion and consensus. Studies that
initially appeared to be relevant but were subsequentlyexcluded were listed in a table of excluded studies with
reasons for their exclusion.
Data extraction and management
Data extraction was carried out in duplicate, independ-
ently, and differences were resolved by discussion and
consensus. Data extraction forms were designed to tabu-
late the characteristics of the included studies. Where
missing information was detected or clarity was needed,
the authors of the primary studies were contacted via
e-mail. Variables for which data were sought included
study design, treatment and comparator, total number of
participants at beginning and end of trial in intervention
and control groups, length of treatment in days, out-
comes, main results and adverse events reported.
Assessment of quality of evidence
Two reviewers independently assessed the components
of each trial for risk of bias, at study level. The Cochrane
“risk of bias” assessment tool [18] was used to assess the
potential sources of bias in the methodology of the
included trials. The domains assessed were sequence
generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting, and other
potential threats to validity. Assessment was done by an-
swering a pre-specified question about the adequacy of
each individual study in relation to the entry, in such a
way that the judgment of ‘yes’ was indicative of low risk
of bias, ‘no’ was indicative of high risk of bias, and
‘unclear’ was indicative of uncertain risk of bias. Disagree-
ments were resolved with discussion and consensus.
Measures of treatment effect and data synthesis
Dichotomous outcomes (including adverse events, nausea
and vomiting) were expressed as risk ratios (RR) with 95%
confidence intervals (CI). Continuous outcomes such as
symptom scores (for example, as measured by a VAS), were
expressed as mean differences (MD) with 95% CI’s.
Heterogeneity was assessed by both the visual inspection of
the forest plots (where non-overlapping of confidence inter-
vals indicated the likelihood of heterogeneity) and by using
the Chi2-test for heterogeneity (differences at the level
of p < 0.05 were considered to be statistically signifi-
cant). Heterogeneity was also expressed as the I2 statis-
tic, [18] with a value of 0% indicating no heterogeneity.
The investigators undertook to assess funnel plots to
explore the possibility of small study and other bias
where at least ten studies were included per meta-
analysis [18].
The Review Manager 5.0 (RevMan 5) computer pro-
gram (developed by the Cochrane Collaboration) was
used for data entry and statistical analysis of the data. A
random effects model of meta-analysis was used in the
presence of moderate heterogeneity of treatment effects,
Records identified through 
database searching
(N=302)
Records screened
(N=185)
Full-text articles assessed
eligibility
(N=54)
Included studies 
(N=12)
Full-text articles excluded, 
with reasons
(N=42)
- Study type (N=30)
- Brief items/letters/comment (N=9)
- Intervention (not ginger) (N=1)
- Foreign language (N=2)
Records excluded
(N=131)
-Study type (N=100)
-Brief items/letters/comment (N=7)
-Intervention (not ginger) (N=5)
-Participants (not pregnant) (N=16)
-Animal research (N=3)
Duplicates removed
(N=117)
Figure 1 Diagrammatic representation of the process followed
in the selection of studies.
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The Mantel-Haenszel (M-H) method of meta-analysis
was used for dichotomous outcomes and the Inverse-
Variance (IV) method was used for continuous outcomes.
All statistical methods used were confirmed by a statisti-
cian trained in meta-analyses and systematic reviews.
Subgroup and sensitivity analyses
The planned subgroup analyses to explore possible
sources of heterogeneity included different dosages ad-
ministered in the various studies [low (<1500 mg ginger/
day) vs. high (≥ 1500 mg ginger/day)] and different dura-
tions of intervention in the various studies [short treat-
ment (<7 days) vs. long treatment (≥7 days)]. Sensitivity
analyses were planned to explore the influence of study
quality and source of funding on effect size, should
sufficient studies exist.
Results
Study selection
The process followed in the selection of studies and the
results obtained from the search are shown in Figure 1.
Across all searched databases (and reference lists
reviewed) 302 abstracts were identified as potentially
relevant. Of these, 117 studies were identified as dupli-
cates. In the case of duplicate publications, the original
paper (or the oldest version) was used. A further 173
were excluded, in 2 phases, for various reasons (Figure 1).
Finally, twelve studies [19-30] met the aforementioned
criteria and were included. Although foreign language
studies were excluded from this review, all potentially
eligible studies reported in languages other than English
were documented for future assessment [31,32].
Study characteristics
Included studies were published from 1991 to 2011. Key
characteristics of the included studies are presented in
Table 1 and arranged alphabetically. Eleven (91.6%) of
the twelve included trials were designed as parallel group
studies. Only one study [22] had a cross-over design. A
total of 1278 participants were included in the respective
studies, ranging from 26 in the smallest trial [23] to 291
participants in the largest trial [27]. Only 2 trials [26,27]
recruited more than 150 participants. Eleven of the
twelve included studies [19-21,23-30] (91.6%), included
women suffering from NVP, and one study [22] (8.3%)
included women suffering from HG. The study interven-
tion (ginger) was clearly described in each included
study. Most of the studies (n = 8) (66.7%) [20-22,25-29]
used ginger powder capsules as intervention, ranging
from 1000 mg to 1950 mg ginger per day. One study
[19] (8.3%) used ginger biscuits as intervention, with a
total dose of 2500 mg ginger per day. One study [23]
(8.3%) used a total of 1000 mg ginger syrup per day,dissolved in water; one study [30] (8.3%) used 1000 mg
ginger extract per day, in capsule form; and one study
[24] used a total of 600 mg ginger essence per day. The
comparator was clearly described in most of the in-
cluded studies [20-23,25-28,30]. A placebo was used as
the control in 7 studies. Two studies [22,25] used lactose
as the placebo, one used lemon oil [23], one used flour
[24], and one used soy bean oil [30]. One study [19] used
placebo biscuits but did not specify the content of the
biscuit, and one study [29] did not specify the content of
the placebo capsule. Four studies used Vitamin B6 as
active comparator. Two studies [20,27] used 70 mg per
day, one [21] used 40 mg per day and one [28] used
30 mg Vitamin B6 per day. One study [24] used 30 mg
Metoclopramide as comparator, as well as placebo. The
remaining study [26] used 100 mg Dimenhydrinate per
day as active comparator (Table 1).
Table 1 Characteristics of included studies
Study ID Risk of
bias
NPB/NME
(treatment)
Intervention
(ginger dose/day)
Comparator*
(dose per day)
L of T
(days)
Main outcome measures Main results
Basirat [19] High 65/62
(32G, 30C)
Ginger biscuits
(500 mg 5 times
daily = 2500 mg/day)
Placebo biscuit (5 biscuits
per day, dose not specified)
4 Severity of nausea (VAS 0–10); number
of vomiting episodes; general response
to treatment (5-item Likert scale)
Ginger biscuits provided significantly
greater relief from the severity of nausea
(p = 0.01), and to some extent vomiting
(p = 0.24).
Chittumma [20] High 126/123
(61G, 62C)
Ginger powder
capsules (325 mg ×2,
three times daily, =
1950 mg/day)
Vitamin B6 capsules
(12.5 mg ×2, three times
daily =75 mg/day)
4 Change in nausea and vomiting scores
(3 symptoms on Rhodes index);
occurrence of side-effects
Results showed that ginger is
significantly more effective in relieving
NVP than vitamin B6 (p < 0.05).
Ensiyeh [21] High 70/69
(35G, 34C)
Ginger powder
capsules (500 mg
2×/d =1000 mg/day)
Vitamin B6 capsules (20 mg
twice per day =40 mg/day)
4 Severity of nausea (VAS 0–10); number
of vomiting episodes; general response
to treatment (5-item Likert scale);
occurrence of side-effects or adverse
pregnancy outcome
The results showed that the ginger is
significantly more effective than vitamin
B6 for relieving the severity of nausea
(p < 0.024), and equally effective for
reducing the number of vomiting
episodes.
Fischer-
Rassmussen [22]
Mode-rate 30/27
(27G, 27C)
(cross-over**)
Ginger powder
capsules (250 mg
4 times per day =
1000 mg/day)
Placebo capsules (lactose)
(250 mg 4 times per day =
1000 mg/day)
4 Preference of treatment period; relief
scores (4-point scoring system);
outcome of pregnancy
The results showed that ginger was
significantly more effective than the
placebo in eliminating or minimizing
HG (p = 0.035).
Keating [23] High 26/21
(12G, 9C)
Ginger syrup in
water (250 mg
4 times per day =
1000 mg/day)
Placebo syrup (lemon oil)
4x/day (dose not specified)
14 Level of nausea (numerical scale 1–10);
number of vomiting episodes
Ginger had a greater effect on the
relieving of NVP, but due to the small
study sample the results were not
statistically analyzed. The authors
concluded that ginger syrup may be
more effective than placebo syrup in
treatment of NVP.
Mohammadbeigi
[24]
High 102/102
(34G, 34C1,
34C2)
Ginger essence
capsules (200 mg
3×/day = 600
mg/day)
1. Metoclopramide capsules
(10 mg 3×/day = 30 mg/day)
5 Used RINVR to measure severity of
nausea and vomiting.
Ginger was less effective than
metoclopramide in reducing nausea
and vomiting during pregnancy, but
the difference was not statistically
significant (p = 0.509).
2. Placebo capsules (flour)
(200 mg 3×/day = 600 mg/day)
Ozgoli [25] Mode-rate 70/67
(32G, 53C)
Ginger powder
capsules (250 mg
4 times per day =
1000 mg/day)
Placebo capsules (lactose)
(250 mg 4 ×/d 1000 mg/day)
4 Nausea intensity (VAS 0–10); number
of vomiting incidences
The results showed that ginger was
significantly more effective than the
placebo in improving symptoms of
NVP (p < 0.05).
Pongrojpaw [26] High 170/151
(77G, 74C)
Ginger powder
capsules (500 mg
2x/d =1000 mg/day)
Dimenhydrinate capsules
(50 mg 2x/d = 100 mg/day)
7 Degree of nausea (VAS 0–10); number
of vomiting incidences; occurrence
of side-effects
There was no significant difference in
the visual analogue nausea scores
between the two groups. Ginger
was as effective as dimenhydrinate in
the treatment of NVP, and has fewer
side-effects.
Smith [27] High 291/235
(120G, 115C)
Ginger capsules
(350 mg 3times per
day = 1050 mg/day)
Vitamin B6 capsules (25 mg
3x/d =75 mg/day)
21 Nausea, vomiting and dry retching
on days 0,7,14,21 (Rhodes Index of
Nausea and Vomiting Form2) (5-point
Likert scale); change in health status
on day 0,21 (MOS 36 Short Form Health
The results indicated that ginger is
equivalent to vitamin B6 in improving
nausea, dry retching and vomiting in
pregnancy. All p-values were <0.001.
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Table 1 Characteristics of included studies (Continued)
Survey, 8-multi-item scale, higher
core = better outcome); occurrence of
side-effects and adverse pregnancy
outcomes
Sripramote [28] High 138/128
(64G, 64C)
Ginger powder
capsules (500 mg
3×/d 1500 mg/day)
Vitamin B6 capsules (10 mg
3×/d =30 mg/day)
3 Severity of nausea (VAS 0–10); number
of vomiting incidences; occurrence of
side-effects
Both ginger and vitamin B6 were
effective for treating NVP (p < 0.001).
There were no significant differences
between the two treatments’ efficacy.
Vutyavanich [29] High 70/67
(32G, 35C)
Ginger powder
capsules (250 mg
4x/day =1000
mg/day)
Placebo capsules
(not specified) (250 mg
4x/day = 1000 mg/day)
4 Severity of nausea (VAS 0–10); number
of vomiting episodes; general response
to treatment after 1 week (5-item Likert
scale); occurrence of side-effects and
adverse pregnancy outcomes
Ginger was significantly more effective
than the placebo in relieving the
severity of nausea in pregnancy
(p = 0.014).
Willetts [30] Mode-rate 120/99
(48G, 51C)
Ginger extract
capsules (125 mg
4x/d =1000 mg/day)
Placebo capsules (soy bean
oil 4x/d) (dose not specified)
4 Used RINVR to measure frequency,
duration, distress caused by nausea,
vomiting and retching; long term
follow-up for birth outcome
Ginger was more effective than placebo
for improving nausea and retching
during pregnancy, but no difference
in the vomiting episodes were observed.
No p-values were provided.
*Comparator: includes placebo and active ingredients. **Cross-over design RCT. All the other studies were parallel design RCT’s.
RCT: Randomized controlled trial; NVP: Nausea and vomiting of pregnancy; HG: Hyperemesis gravidarum; NPB: Number of patients at beginning of trial; NPE: Number of patients at end of trial; L of T: Length of
treatment; G: patients in Ginger group; C: patients in comparator group C1: control group nr 1; C2: control group nr 2; VAS: Visual analogue scale; MOS: Medical outcome study; RINVR: Rhodes Index of Nausea,
Vomiting and Retching. 5-point Likert type tool with 8 items.
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Nausea (the feeling of being about to vomit) is a subject-
ive feeling, and several tools have been developed to reli-
ably measure it. In contrast to nausea, vomiting is a
readily observable occurrence that can be measured or
reported without information from the patient. Still, the
distress caused by vomiting cannot be observed by an-
other person, and remains a subjective feeling. The in-
cluded studies used a variety of tools to measure nausea
severity and vomiting incidences. Six of the studies
[19,21,25,26,28,29] used a visual analogue scale (VAS) of
0–10 centimeters to score nausea severity, and partici-
pants recorded the number of vomiting episodes daily.
One study [23] used a numerical scale of 1–10 for scor-
ing nausea severity, as well as daily recording of vomit-
ing episodes. Four studies [20,24,27,30], used the Rhodes
Index of Nausea and Vomiting, or parts of this index, to
measure both nausea and vomiting, and the remaining
study [22] used a 4 point system to score nausea and
vomiting symptoms.
General response to treatment
The tools used in the included studies to measure the
general response to treatment outcome were Likert
scales [19,21,29], a point-system instrument [22] and the
Medical outcome survey (MOS) Short form-36 Health
Survey [27,33].
Adverse events and side-effects
The judgments made on the seriousness of the reported
side-effects or adverse events are the author team’s own
subjective judgments, also taking into account the fact
that some of these events can occur in a normal preg-
nancy, without any interventions. Adverse events and
side effects were classified as major when it was consid-
ered a serious complication, possibly being detrimental
to the mother or fetus. Major events reported across the
studies were allergic reaction [30], arrhythmia [20], de-
hydration [30], and spontaneous abortion [21,22,29].
Events were classified as minor when considered a dis-
comfort, but manageable side-effects. Minor events re-
ported across the studies included abdominal discomfort
[29], belching [27], burning sensation after capsule in-
gestion [27], diarrhea [29], dry retching or vomiting after
capsule ingestion [27], headaches [20,29], drowsiness
[19,20,26,28] and heartburn [19,20,26,28-30].
Methodological quality
All included trials were RCT’s. The Cochrane “risk of
bias” assessment tool [18] was completed for each of the
included studies to assess methodological quality and
to enable data entry into the RevMan 5 program. The
author team’s judgments about each methodological
quality assessment factor across all included studies aredemonstrated in Figure 2, and indicate high risk of bias
in especially the “blinding” and “other bias” categories.
All included studies were concluded to be either at high
[19-21,23,24,26-29] or moderate [22,25,30] risk of bias.
Only one [19] of the twelve studies (8.3%) had no risk
of other bias. Six [22-25,27,30] of the studies (50%) had
an unclear risk of other bias, and five [19,21,26,28,29]
studies (41.6%) had a high risk of other bias. The high
risk studies all included dietary counseling as part of
their treatment in both the experimental and the control
groups. The authors considered this as a possible con-
founding factor, since change in outcome scores could
be affected by the dietary adjustments made, rather than
the intervention itself. No reporting was done on the
dietary measures in any of these mentioned studies.
Effect of interventions
The included studies were split into four groups, accord-
ing to the comparison substance used. Placebo was used
in seven studies (considered a control substance). Four
studies used Vitamin B6, one study used Dimenhydrinate,
and one study used Metoclopramide as comparator (these
three substances were considered active ingredients, and
not controls). The Metoclopramide study compared gin-
ger to both Metoclopramide and placebo.
The analyses for the different active ingredients were
done separately as these were different comparisons and
they could not be pooled in one meta-analysis. Subgroup
analyses addressing dosage and duration aspects were
performed for the primary objectives, namely the effect-
iveness of ginger for reduction in nausea and vomiting.
No sensitivity analyses were performed as a result of an
insufficient number of studies per comparison group.
There were insufficient studies per comparison and
outcome to permit the use of funnel plots to assess
publication bias.
Comparison 1: Ginger versus Placebo
Seven studies assessed the effect of ginger versus
placebo [19,22-25,29,30].
Improvement in nausea symptoms
All seven studies assessing the effect of ginger versus
placebo reported this outcome but their results could
not all be pooled in a meta-analysis. Two studies [19,29]
reported the reduction in the visual analogue scale of
post-therapy minus baseline nausea as mean and standard
deviation (SD) and results were pooled in a meta-analysis.
Ginger significantly decreased nausea symptoms when
compared to placebo (MD 1.20, 95% CI: 0.56 to 1.84,
p = 0.0002) (Figure 3) and there was no significant hetero-
geneity detected between the two studies (Chi2 = 0.00,
p = 1.00, I2 = 0%). There were no significant subgroup
differences between the higher dose (≥1500 mg daily) and
Figure 2 Methodological quality graph: judgments about each methodological quality item presented as percentages for all included
studies (n = 12).
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provement in nausea symptoms (change in VAS scores)
(Chi2 = 0.00, p = 1.00, I2 = 0%). No subgroup analysis with
respect to duration was undertaken, as the two studies
had the same duration of 4 days.
One study [24] reported improvement in nausea sever-
ity using a Rhodes Index questionnaire during days 1–5.
The observed trend showed a significant reduction in
nausea severity in favor of ginger compared to the pla-
cebo group (p = 0.003) at the second to fifth day of treat-
ment compared to the first day.
Two studies [23,25] reported this outcome in terms of
the number of women showing improvement in nausea
symptoms (again measured by VAS scores). Meta-analysis
of the results from these two studies shows that ginger
failed to decrease nausea symptoms when compared to
the placebo (RR 2.00, 95% CI: 0.77 to 5.19, p = 0.15) and
there may be moderate heterogeneity between the two
studies (Chi2 = 2.42, p = 0.12, I2 = 59%). There were
no subgroup differences between the longer duration
(≥7 days) and the shorter duration (<7 days) with
respect to the improvement in nausea symptoms
(number showing significant improvement) (Chi2 = 2.04,
p = 0.15, I2 = 50.9%). No subgroup analysis with respect to
dose was undertaken, as the two studies had the same
dosage of 1000 mg/day.
One study [30] reported the trend in mean nausea
experience scores for both the ginger and placebo
groups in the form of a figure only, from which no meanStudy or Subgroup
Basirat 2009
Vutyavanich 2001
Total (95% CI)
Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 3.67 (P = 0.0002)
Mean
2.6
2.1
SD
1.77
1.9
Total
32
32
64
Mean
1.4
0.9
SD
1.62
2.2
Total
30
35
65
W
5
4
10
Ginger Placebo
Figure 3 Forest plot of the improvement in nausea symptoms measuand SD values could be extracted. No treatment effect
could therefore be calculated.
The remaining study [22] was a crossover study which
reported the relief scores on symptoms of a combination
of nausea, vomiting, change in body weight, and patient’s
opinion about the treatment. The observed values for
the relief scores were reported for each patient during
the two periods of the crossover study in the form of a
table. These values were used in calculating the mean
difference (MD) and its standard error (SE) using a
paired analysis and the 95% CIs were calculated using
the generic-inverse variance method in RevMan 5. A sig-
nificantly greater relief of the symptoms was found after
ginger treatment compared to the placebo (MD 3.52,
95% CI: 0.27 to 6.77).
Reduction in the number of vomiting episodes
All seven studies in this comparison reported a reduc-
tion in the number of vomiting episodes, but not all
their results could be pooled in a meta-analysis. Two
studies [19,29] reported this outcome in the form of
mean and SD, and their results could be pooled in a
meta-analysis. According to the meta-analysis, ginger
failed to significantly reduce the number of vomiting
episodes compared to the placebo, although it did ap-
proach significance (MD 0.72, 95% CI: −0.03 to 1.46,
p = 0.06) and statistically significant heterogeneity was
detected between the two studies (Chi2 = 3.44, p = 0.06,
I2 = 71%). There were no significant subgroup differenceseight
7.5%
2.5%
0.0%
IV, Fixed, 95% CI
1.20 [0.36, 2.04]
1.20 [0.22, 2.18]
1.20 [0.56, 1.84]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours placebo Favours ginger
red by change in VAS scores (ginger versus placebo).
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dose (<1500 mg daily) with respect to the reduction in
the number of vomiting episodes (Chi2 = 3.44, p = 0.06,
I2 = 71%). No dose–response effect was found for this
outcome.
One study [24] reported improvement in vomiting se-
verity using a Rhodes Index questionnaire during days
1–5. The observed trend showed a significant reduction
in vomiting severity in favor of ginger compared to the
placebo group (p = 0.046) at the second to fifth day of
treatment compared to the first day.
One study [22] reported vomiting in conjunction
with nausea scores (as discussed in previous section).
One study [23] reported the number of women who
stopped vomiting by day 6 of treatment. Treatment
with ginger failed to reduce the number of women who
stopped vomiting by day 6, when compared to the
placebo treatment (RR 3.33, 95% CI: 0.91 to 12.26).
One study [25] reported that incidence of vomiting
decreased by 50% in the ginger group and 9% in the
placebo group, but this information is insufficient for
calculation of a treatment effect. One study [30] only
reported that there was no significant difference be-
tween ginger extract and placebo groups for any of the
vomiting symptoms but failed to give any values for
the calculation of a treatment effect, as mentioned
earlier.General response to treatment
Only 3 of the 12 studies included in this SR reported on
this outcome. One study [19] reported that ginger did
not significantly result in better responses to the treat-
ment, when compared to the placebo.The occurrence of adverse events and side effects
Four studies [19,23,25,29] reported that none of the par-
ticipants experienced any adverse events from ginger
during the treatment period.
One study [22] reported that one patient had a spon-
taneous abortion and one patient asked for a legal abor-
tion. Because this trial had a crossover design and all
patients received both treatments, no treatment effect
could be calculated for the occurrence of spontaneous
abortion after the treatment period.
For all reported adverse events and side-effects in the
various studies [including allergic reaction [30], dehydra-
tion [30], spontaneous abortions [29,30], abdominal dis-
comfort [29], diarrhea [29], drowsiness [19], headache
[29], heartburn [19,29,30], worsening of symptoms re-
quiring pharmaceutical treatment [30] there were no
significant differences between the ginger and placebo
treated groups (Table 2).Comparison 2: Ginger versus Vitamin B6
Four of the included studies assessed the effect of ginger
versus vitamin B6 [20,21,27,28].
Improvement in nausea symptoms
All four studies assessing the effect of ginger versus vita-
min B6 reported this outcome, but their results could
not all be pooled in a meta-analysis. Two studies [21,28]
reported the reduction in the VAS scores of post-therapy
minus baseline nausea as mean and SD and their results
were pooled in a meta-analysis. According to this meta-
analysis, ginger failed to significantly decrease nausea
symptoms when compared to vitamin B6 (MD 0.34, 95%
CI: −1.52 to 2.20, p = 0.72) and significant heterogeneity
was detected between the two studies (Chi2 = 10.64,
p = 0.001, I2 = 91%). There were significant subgroup
differences between the higher dose (≥1500 mg daily)
and the lower dose (<1500 mg daily) with respect to
the improvement in nausea symptoms (change in VAS
scores) (Chi2 = 10.64, p = 0.001, I2 = 90.6%) (Figure 4).
This implies a dose–response effect for this outcome in
favour of the lower dosage. The different dosages between
the two studies may be the source of heterogeneity detected
in this meta-analysis.
No subgroup analysis with respect to duration was
undertaken, as the two studies had the similar short du-
rations of 4 days and 3 days.
One study [27] reported the reduction in nausea
symptoms from baseline using the Rhodes Index of
Nausea (ranging from 0 to 12, with larger scores indi-
cating more symptoms). The results were reported in
the form of mean and standard error (SE) and these
values were used in calculating the SDs. The means
and SDs were used in calculating the mean difference
(MD) and its 95% CIs. There was no statistically sig-
nificant improvement of nausea symptoms with ginger
treatment compared to vitamin B6 treatment (MD −0.3,
95% CI: −0.85 to 0.25).
The remaining study [20] reported the reduction in
nausea vomiting scales (episodes of nausea, duration of
nausea, and number of vomits) using a modified Rhodes’
score. The results were reported in form of mean and
SD and were used in calculating the MD which showed
that ginger treatment significantly improved the nausea
and vomiting symptoms compared to vitamin B6 treat-
ment (MD 0.70, 95% CI: 0.20 to 1.20).
Reduction in the number of vomiting episodes
All four studies in this comparison group reported a re-
duction in the number of vomiting episodes, but not all
the results could be pooled in a meta-analysis. Results
from three studies [21,27,28] were reported in the form
of mean and SD which were pooled in a meta-analysis.
According to this meta-analysis, ginger failed to reduce
Table 2 Pooled estimates of effect size (95% confidence intervals) expressed as weighted relative risk for adverse
events and side-effects of ginger versus control group (Placebo, Vitamin B6, Dimenhydrinate)
Outcome Number of studies RR 95% CI Heterogeneity
Chi2 I2 (%)
Ginger versus placebo
#Allergic reaction [30] 1 3.00 0.12 to 72.20
#Dehydration [30] 1 3.00 0.12 to 72.20
#Spontaneous abortions [29,30] 2 3.14 0.65 to 15.11 0.00 0
Abdominal discomfort [29] 1 3.27 0.14 to 77.57
Diarrhea [29] 1 3.27 0.14 to 77.57
Drowsiness [29] 1 2.82 0.12 to 66.62
Headache [29] 1 1.31 0.44 to 3.89
Heartburn[19,29,30] 3 5.03 0.89 to 28.61 0.35 0
Worsening of symptoms requiring pharmaceutical treatment [30] 1 0.33 0.01 to 8.02
Ginger versus vitamin B6
#Arrhythmia [20] 1 0.51 0.05 to 5.46
#Spontaneous abortions [21,27] 2 0.49 0.17 to 1.42 1.67 40
Belching [27] 1 27.18 1.63 to 453.06*
Burning sensation after capsule ingestion [27] 1 1.01 0.21 to 4.91
Drowsiness [20,28] 2 0.75 0.48 to 1.19 0.18 0
Dry retching [27] 1 0.93 0.76 to 1.15
Heartburn [20,28] 2 2.35 0.93 to 5.93 1.03 3
Vomiting [27] 1 1.51 0.26 to 8.91
Ginger versus Dimenhydrinate
Drowsiness [26] 1 0.08 0.03 to 0.18**
Heartburn [26] 1 1.44 0.65 to 3.20
#Major adverse events (serious complications, possibly detrimental to the mother or fetus) (authors’ judgement); rest considered minor (discomfort, but
manageable side effects) - sorted alphabetically, first major then minor events.
*Indicates significant finding: Ginger significantly increased the risk of belching compared to vitamin B6.
**Indicates significant finding: Dimenhydrinate significantly increased the risk of drowsiness compared to ginger.
RR, Relative risk; CI, confidence interval.
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vitamin B6 (MD −0.07, 95% CI: −0.48 to 0.35, p = 0.76)
and there may have been moderate heterogeneity be-
tween the three studies (Chi2 = 3.58, p = 0.17, I2 = 44%).
There were no significant subgroup differences between
the higher dose (>1500 mg daily) and the lower dose
(<1500 mg daily) with respect to the reduction in the num-
ber of vomiting episodes (Chi2 = 0.72, p = 0.40, I2 = 0%).
Similarly there were no significant subgroup differences
between the longer duration (≥7 days) and the shorter dur-
ation (<7 days) with respect to the reduction in the number
of vomiting episodes (Chi2 = 3.51, p = 0.06, I2 = 71.5%).
The remaining one study [20] reported vomiting in
conjunction with nausea as mentioned above.
General response to treatment
A meta-analysis of two studies [21,27] showed that gin-
ger did not significantly increase the number reporting
improvement when compared to vitamin B6.The occurrence of adverse events and side-effects
Two studies [20,28] reported that none of the partici-
pants experienced any adverse events from either ginger
or vitamin B6 during the treatment period.
Ginger significantly increased the risk of belching com-
pared to vitamin B6 (RR 27.18, 95% CI: 1.63 to 453.06) in
one study [27]. For all other adverse events and
side-effects reported in the various studies [including
arrhythmia [20], spontaneous abortions [21,27], burning
sensation after capsule ingestion [27], drowsiness [20,28],
dry retching [27], heartburn [20,28], vomiting [27]] there
were no significant differences between the ginger and
Vitamin B6 treated groups (Table 2).
Comparison 3: Ginger versus Dimenhydrinate
Only one included study [26] assessed the effect of gin-
ger versus dimenhydrinate. This study reported a reduc-
tion in the VAS scores of post-therapy minus baseline
nausea, as well as reduction in the number of vomiting
Study or Subgroup
2.1.1 Higher dose (>=1500mg daily)
Sripramote 2003
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
2.1.2 Lower dose (<1500mg daily)
Ensiyeh 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.00 (P = 0.003)
Total (95% CI)
Heterogeneity: Tau² = 1.64; Chi² = 10.64, df = 1 (P = 0.001); I² = 91%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi² = 10.64, df = 1 (P = 0.001), I² = 90.6%
Mean
1.4
2.2
SD
2.21
1.9
Total
64
64
35
35
99
Mean
2
0.9
SD
2.19
1.7
Total
64
64
34
34
98
Weight
50.5%
50.5%
49.5%
49.5%
100.0%
IV, Random, 95% CI
-0.60 [-1.36, 0.16]
-0.60 [-1.36, 0.16]
1.30 [0.45, 2.15]
1.30 [0.45, 2.15]
0.34 [-1.52, 2.20]
Ginger Vitamin B6 Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours vitamin B6 Favours ginger
Figure 4 Forest plot of the improvement in nausea symptoms as measured by the change in VAS scores (ginger versus Vitamin B6):
subgroup analysis regarding dose (≥1500 mg versus < 1500 mg).
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mean and SD values could be extracted. No treatment
effect could therefore be calculated.
No adverse events were reported. The study reported
results on drowsiness (minor side effect), with dimenhy-
drinate significantly increasing the risk of drowsiness
compared to ginger (RR 0.08, 95% CI: 0.03 to 0.18). The
study also reported results on heartburn (minor side
effect) and there was no statistically significant difference
found between the ginger and dimenhydrinate treated
groups (Table 2).
Comparison 4: Ginger versus Metoclopramide
Only one included study [24] assessed the effect of
ginger versus metoclopramide.
Improvement in nausea symptoms
One study [24] reported improvement in nausea severity
using a Rhodes Index questionnaire during days 1 to 5.
There was no significant difference in the observed
trend in nausea severity between the ginger and meto-
clopramide groups (p = 0.683) at the second to fifth day
of treatment compared to the first day.
Improvement in vomiting
One study [24] reported improvement in vomiting sever-
ity using a Rhodes Index questionnaire during days 1 to
5. There was no significant difference in the observed
trend in vomiting severity between the ginger and meto-
clopramide groups (p = 0.718) at the second to fifth day
of treatment compared to the first day. No adverse
events were reported in this study.Discussion
Literature indicate that the exact cause and treatment of
NVP is still unclear [2,6,17,34-37]. Mothers and health
practitioners often investigate alternative options to alle-
viate symptoms of NVP, due to the possible harmful side
effects that conventional medicine may pose to the un-
born fetus. In this regard, ginger is considered by many
as a possible non-pharmacological treatment option for
NVP. This updated systematic review has investigated
the current evidence-base and supports and strengthen
previous findings that ginger could be considered a harm-
less and possibly effective alternative option for women
suffering from the symptoms of NVP.
Primary outcomes
Symptomatic relief of nausea, number of vomiting episodes
and general response to treatment
Ginger versus placebo was assessed in seven of the in-
cluded studies [19,22-25,29,30]. Individually, all seven
studies concluded that ginger was more effective than
the placebo in relieving the intensity of nausea, or NVP
in general. One meta-analysis of two studies [19,29] in
this SR showed that ginger significantly decreased nau-
sea symptoms when compared to placebo. When taking
into account that other SRs [10,16,17,35,36] as well as
the above-mentioned 7 concluded that ginger had bene-
ficial effects on nausea during pregnancy (together with
the findings of this SR), it is probably safe to assume that
ginger has potential as a possible anti-emetic drug-
alternative during pregnancy. The theoretical physio-
logical mechanism by which ginger affects the digestive
system also supports this theory. Ginger can increase
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therefore increasing the gastro-intestinal transit time of
meals, which can decrease the feeling of nausea [15].
Although three [22,25,29] of the seven studies that
assessed ginger versus placebo concluded individually
that ginger was more effective than placebo in reducing
the number of vomiting episodes, the remaining evi-
dence and meta-analysis performed lead to the conclu-
sion that ginger did not significantly reduce the number
of vomiting episodes during NVP when compared to the
placebo. A meta-analysis of three studies [21,27,28]
showed that ginger did not significantly reduce vomiting
episodes when compared to vitamin B6. Based on this
currently available evidence, the author team concludes
that ginger does not seem to reduce the number of vomit-
ing episodes significantly when compared to vitamin B6.
Due to the small number of studies reporting on the
outcome of general response to treatment, no conclu-
sions can be drawn in this regard.
Secondary outcomes
Adverse events and side-effects
The author team made subjective judgments to classify
the occurring adverse events and side-effects as major
(serious complications detrimental to the mother or
fetus, including arrhythmia, spontaneous abortion, aller-
gic reaction to treatment, and dehydration), or minor
(discomfort, but manageable side-effects). According to
the available evidence (Table 2), ginger significantly in-
creased the risk of belching compared to vitamin B6
(bearing in mind the very large CI indicating poor preci-
sion and thus limiting firm conclusions). Dimenhydrinate
significantly increased the risk of drowsiness compared to
ginger. Ginger therefore does not seem to pose a risk for
any major side-effects or adverse events occurring, and
thus no risk for any serious complications detrimental to
the mother or fetus.
Comparisons with other studies
The findings of this updated SR compare well with the find-
ings of previously conducted reviews [10,14,16,17,34-36]
on the same topic. Limited meta-analysis could be per-
formed, often due to the heterogeneity in participants,
interventions, outcome measures and comparison groups
encountered. This clearly shows the need for more re-
search on the topic, with larger studies and standardization
of methods and materials. All these reviews suggest that
ginger may be effective for the treatment of NVP, but data
is insufficient to draw firm conclusions regarding the
dosage and duration of treatment.
Two recently published systematic reviews on the
same topic support the potential of ginger as a possible
treatment option for NVP [35,36]. The SR by Ding et al.
[35] included studies published from 2000–2009 andincluded 4 RCTs [23,25,27,30], all of which were also
included in the current SR. This group reported that
ginger was more effective than placebo, and as effective
as Vitamin B6 in improving NVP. They concluded that
ginger use for NVP were safe, but highlighted the need
for further studies with longer duration, to establish the
long term safety and effectiveness of ginger.
The SR by Thomson et al. [36] was published early in
2014 and included six studies [19,22,23,25,27,29], all of
which were also included in the current SR. This meta-
analysis indicated that ginger is better than placebo in
improving NVP (RR 1.76, 95% CI: 1.18 to 2.65).
Both these recent systematic reviews used the ap-
proach of comparing ginger to placebo (both also in-
cluding one study comparing ginger to Vitamin B6 [27]).
This current updated SR builds substantially on previous
reviews by including a recent literature search and
grouping all comparators into four groups (placebo,
Vitamin B6, dimenhydrinate and metoclopramide), as
any other treatment than placebo was considered an
active ingredient.
Practice points
From a practice point of view, the subgroup analysis per-
formed indicated that the lower dosage of <1500 mg gin-
ger per day could possibly be more effective than the
higher dosage of ≥1500 mg (again, bearing in mind the
limited value of the small subgroup analyses). Most
studies provided 1000 mg of ginger powder for a period
of 4 days to women suffering from NVP (with no
apparent side-effects or adverse events). The litera-
ture suggests taking the total dose in three to four
divided doses during the day, irrespective of meal-
times [21-23,25,26,29,30]. Mothers can be advised to
use ginger freely in their cooking, to drink ginger tea and
soft drinks, and to have dry ginger biscuits as needed.
Strengths and limitations
This updated SR includes the latest trials related to the
topic, with the last search for studies performed in July
2013. The small sample sizes and few study numbers
analyzed per outcome, as well as differences in dosage
and duration of treatment lead to high levels of incon-
sistency and heterogeneity in the results of the review.
Unfortunately, many of the included studies did not
present data in a usable form for inclusion in meta-
analysis, or similar outcomes were reported differently
and could not be pooled together. These factors limit
the strength of evidence and cause some degree of
uncertainty when interpreting the results. None of the
twelve studies included in this SR described any form of
chemical or chromatographic tests to verify the exact
composition of the active compounds in the ginger prep-
arations. Another limitation of this SR is the inclusion of
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studies were documented for possible future inclusion.
As with many nutrition-related research studies, it is
difficult to control every exposure and it is almost
impossible to keep all dietary exposures identical for
all participants. Ginger has a very characteristic and
recognizable taste, which makes it difficult to mask dur-
ing trials. This could act as a potential confounder, as it
can be considered “unblinding” in some cases. A pos-
sible solution to this problem is to do pre-trial testing,
as was done in the study by Vutyavanich et al., [29] to
test if the patients are able to identify the treatment
before the start of the trial. Publication bias is always a
concern when a SR is conducted, as it is known that
studies with negative results are often not published.
Ginger is considered a complementary and/or alternative
medicine (CAM) [37]. The publication of literature on
CAM therapies might be suboptimal [10,37]. As with all
SRs, there was potential for bias at all stages of the
reviewing process. Minimizing bias was attempted by
having two independent reviewers undertaking study
selection, data extraction and quality assessment.
Conclusion
This review suggests potential benefits of ginger in redu-
cing nausea symptoms in pregnancy (bearing in mind
the limited number of studies, variable outcome report-
ing and low quality of evidence). Subgroup analyses
seemed to favor the lower daily dosage of <1500 mg gin-
ger for nausea relief. Ginger did not have a significant
impact on vomiting episodes, nor pose a risk for side-
effects or adverse events during pregnancy. Based on
evidence from this SR, ginger could be considered a harm-
less and possibly effective alternative option for women
suffering from the symptoms of NVP. Large standardized
randomized controlled trials are necessary to confirm the
possible benefit of ginger as treatment for NVP.
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